<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36879067</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course.</ArticleTitle><Pagination><StartPage>604</StartPage><EndPage>611</EndPage><MedlinePgn>604-611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-023-01445-w</ELocationID><Abstract><AbstractText>Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1&#x2009;yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Muri</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6476-3766</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cecchinato</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7415-8706</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4063-4502</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland. andrea.cavalli@irb.usi.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Institute of Bioinformatics, Lausanne, Switzerland. andrea.cavalli@irb.usi.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanbhag</LastName><ForeName>Akanksha A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matkovic</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biggiogero</LastName><ForeName>Maira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maida</LastName><ForeName>Pier Andrea</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toscano</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghovehoud</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0366-2670</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlan</LastName><ForeName>Raffaello</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbic</LastName><ForeName>Franca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8283-1988</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voza</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Nadai</LastName><ForeName>Guendalina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Emergency Medicine Residency School, Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervia</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7120-8739</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurbuchen</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5387-9950</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taeschler</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0522-7629</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Lilly A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-6153-5277</Identifier><AffiliationInfo><Affiliation>Lyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danelon-Sargenti</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piffaretti</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crivelli</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pode&#x161;vov&#xe1;</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedotti</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarrossay</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgrignani</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhr</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Synlab Suisse, Bioggio, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Enos</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9724-8373</Identifier><AffiliationInfo><Affiliation>Regional Hospital Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe0; della Svizzera italiana, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Andri</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5297-6062</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciurea</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7870-7132</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>Marco B L</ForeName><Initials>MBL</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Biostatistics Unit, University of Urbino, Urbino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varani</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0963-0987</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Infection &amp; Immunity, Cardiff University School of Medicine, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottazzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1930-9257</Identifier><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3443-1605</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Lyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lyme Research Program at the New York State Psychiatric Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyman</LastName><ForeName>Onur</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8279-5545</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Faculty of Science, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantovani</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5578-236X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The William Harvey Research Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzoni</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzetti-Pellanda</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uguccioni</LastName><ForeName>Mariagrazia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9570-7011</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland. mariagrazia.uguccioni@irb.usi.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy. mariagrazia.uguccioni@irb.usi.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbiani</LastName><ForeName>Davide F</ForeName><Initials>DF</Initials><Identifier Source="ORCID">0000-0001-7379-3484</Identifier><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Universit&#xe0; della Svizzera italiana, Bellinzona, Switzerland. drobbiani@irb.usi.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>198431</GrantID><Acronym>SNSF_</Acronym><Agency>Swiss National Science Foundation</Agency><Country>Switzerland</Country></Grant><Grant><GrantID>P01 AI138938</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI111825</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI151698</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>201369</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2022 Nov 27:2022.05.23.493121. doi: 10.1101/2022.05.23.493121</RefSource><PMID Version="1">35664993</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2023 Apr;24(4):567-569. doi: 10.1038/s41590-023-01455-8</RefSource><PMID Version="1">36922648</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The Institute for Research in Biomedicine has filed a provisional patent application in connection with this work on which J. Muri, V. Cecchinato, A. Cavalli, M. Uguccioni and D.F.R. are inventors. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36879067</ArticleId><ArticleId IdType="mid">EMS172243</ArticleId><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01445-w</ArticleId><ArticleId IdType="pii">10.1038/s41590-023-01445-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat. Commun. 2022;13:446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, et al. Chemokines in homeostasis and diseases. Cell. Mol. Immunol. 2018;15:324&#x2013;334. doi: 10.1038/cmi.2017.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2017.134</ArticleId><ArticleId IdType="pmc">PMC6052829</ArticleId><ArticleId IdType="pubmed">29375126</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e1039. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. Sci. Immunol. 2022;7:eabm5505. doi: 10.1126/sciimmunol.abm5505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abm5505</ArticleId><ArticleId IdType="pubmed">34995097</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput. Struct. Biotechnol. J. 2021;19:976&#x2013;988. doi: 10.1016/j.csbj.2021.01.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.01.034</ArticleId><ArticleId IdType="pmc">PMC7859556</ArticleId><ArticleId IdType="pubmed">33558827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>COMBAT-Consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell. 2022;185:916&#x2013;938.e958. doi: 10.1016/j.cell.2022.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.012</ArticleId><ArticleId IdType="pmc">PMC8776501</ArticleId><ArticleId IdType="pubmed">35216673</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell. 2020;183:1479&#x2013;1495.e1420. doi: 10.1016/j.cell.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendeiro AF, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593:564&#x2013;569. doi: 10.1038/s41586-021-03475-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03475-6</ArticleId><ArticleId IdType="pmc">PMC8204801</ArticleId><ArticleId IdType="pubmed">33780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D, et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184:6243&#x2013;6261.e6227. doi: 10.1016/j.cell.2021.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 2021;6:eabl4340. doi: 10.1126/sciimmunol.abl4340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12:5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12:eabd3876. doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13:eabh2624. doi: 10.1126/scitranslmed.abh2624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611:139&#x2013;147. doi: 10.1038/s41586-022-05273-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump MP, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997;16:6996&#x2013;7007. doi: 10.1093/emboj/16.23.6996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/16.23.6996</ArticleId><ArticleId IdType="pmc">PMC1170303</ArticleId><ArticleId IdType="pubmed">9384579</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437&#x2013;442. doi: 10.1038/s41586-020-2456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Quintela A, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin. Exp. Immunol. 2008;151:42&#x2013;50. doi: 10.1111/j.1365-2249.2007.03545.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2007.03545.x</ArticleId><ArticleId IdType="pmc">PMC2276914</ArticleId><ArticleId IdType="pubmed">18005364</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e820. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect. Dis. 2010;10:875&#x2013;885. doi: 10.1016/S1473-3099(10)70196-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70196-1</ArticleId><ArticleId IdType="pubmed">21109174</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N. Engl. J. Med. 2018;378:2010&#x2013;2021. doi: 10.1056/NEJMra1705454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell. Mol. Life Sci. 2012;69:1435&#x2013;1445. doi: 10.1007/s00018-011-0872-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-011-0872-6</ArticleId><ArticleId IdType="pmc">PMC11114792</ArticleId><ArticleId IdType="pubmed">22045557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin. Exp. Immunol. 2009;155:1&#x2013;15. doi: 10.1111/j.1365-2249.2008.03834.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2008.03834.x</ArticleId><ArticleId IdType="pmc">PMC2665673</ArticleId><ArticleId IdType="pubmed">19076824</ArticleId></ArticleIdList></Reference><Reference><Citation>Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J. Clin. Invest. 2015;125:2194&#x2013;2202. doi: 10.1172/JCI78084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78084</ArticleId><ArticleId IdType="pmc">PMC4497746</ArticleId><ArticleId IdType="pubmed">25938780</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchinato V, et al. Impairment of CCR6+ and CXCR3+ Th cell migration in HIV-1 infection is rescued by modulating actin polymerization. J. Immunol. 2017;198:184&#x2013;195. doi: 10.4049/jimmunol.1600568.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600568</ArticleId><ArticleId IdType="pmc">PMC5164881</ArticleId><ArticleId IdType="pubmed">27895171</ArticleId></ArticleIdList></Reference><Reference><Citation>Stravalaci M, et al. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nat. Immunol. 2022;23:275&#x2013;286. doi: 10.1038/s41590-021-01114-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01114-w</ArticleId><ArticleId IdType="pubmed">35102342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Rivero I, et al. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. J. Autoimmun. 2004;23:63&#x2013;73. doi: 10.1016/j.jaut.2004.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2004.03.013</ArticleId><ArticleId IdType="pubmed">15236754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock E, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370:eabd4250. doi: 10.1126/science.abd4250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4250</ArticleId><ArticleId IdType="pmc">PMC7857405</ArticleId><ArticleId IdType="pubmed">32994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark-Lewis I, Vo L, Owen P, Anderson J. Chemical synthesis, purification, and folding of C-X-C and C-C chemokines. Methods Enzymol. 1997;287:233&#x2013;250. doi: 10.1016/S0076-6879(97)87018-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(97)87018-8</ArticleId><ArticleId IdType="pubmed">9330326</ArticleId></ArticleIdList></Reference><Reference><Citation>Moepps B, Thelen M. Monitoring scavenging activity of chemokine receptors. Methods Enzymol. 2016;570:87&#x2013;118. doi: 10.1016/bs.mie.2015.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mie.2015.11.003</ArticleId><ArticleId IdType="pubmed">26921943</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gasparo R, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593:424&#x2013;428. doi: 10.1038/s41586-021-03461-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03461-y</ArticleId><ArticleId IdType="pubmed">33767445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 2001;97:1920&#x2013;1924. doi: 10.1182/blood.V97.7.1920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V97.7.1920</ArticleId><ArticleId IdType="pubmed">11264152</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaslaver A, Feniger-Barish R, Ben-Baruch A. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2. J. Immunol. 2001;166:1272&#x2013;1284. doi: 10.4049/jimmunol.166.2.1272.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.2.1272</ArticleId><ArticleId IdType="pubmed">11145710</ArticleId></ArticleIdList></Reference><Reference><Citation>Loetscher M, et al. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr. Biol. 1997;7:652&#x2013;660. doi: 10.1016/S0960-9822(06)00292-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(06)00292-2</ArticleId><ArticleId IdType="pubmed">9285716</ArticleId></ArticleIdList></Reference><Reference><Citation>Uguccioni M, D&#x2019;Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1&#x3b1; and MIP-1&#x3b2; on human monocytes. Eur. J. Immunol. 1995;25:64&#x2013;68. doi: 10.1002/eji.1830250113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830250113</ArticleId><ArticleId IdType="pubmed">7531149</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, et al. Recurrent potent human neutralizing antibodies to Zika virus in brazil and Mexico. Cell. 2017;169:597&#x2013;609.e511. doi: 10.1016/j.cell.2017.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.04.024</ArticleId><ArticleId IdType="pmc">PMC5492969</ArticleId><ArticleId IdType="pubmed">28475892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiller T, et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 2008;329:112&#x2013;124. doi: 10.1016/j.jim.2007.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2007.09.017</ArticleId><ArticleId IdType="pmc">PMC2243222</ArticleId><ArticleId IdType="pubmed">17996249</ArticleId></ArticleIdList></Reference><Reference><Citation>von Boehmer L, et al. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat. Protoc. 2016;11:1908&#x2013;1923. doi: 10.1038/nprot.2016.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.102</ArticleId><ArticleId IdType="pubmed">27658009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41:W34&#x2013;W40. doi: 10.1093/nar/gkt382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt382</ArticleId><ArticleId IdType="pmc">PMC3692102</ArticleId><ArticleId IdType="pubmed">23671333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta NT, et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 2015;31:3356&#x2013;3358. doi: 10.1093/bioinformatics/btv359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv359</ArticleId><ArticleId IdType="pmc">PMC4793929</ArticleId><ArticleId IdType="pubmed">26069265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 2020;217:e20201181. doi: 10.1084/jem.20201181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201181</ArticleId><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature. 2016;540:458&#x2013;461. doi: 10.1038/nature20605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20605</ArticleId><ArticleId IdType="pmc">PMC5159191</ArticleId><ArticleId IdType="pubmed">27926736</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaik MM, et al. Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature. 2019;565:318&#x2013;323. doi: 10.1038/s41586-018-0804-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0804-9</ArticleId><ArticleId IdType="pmc">PMC6391877</ArticleId><ArticleId IdType="pubmed">30542158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasilko DJ, et al. Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. Nat. Commun. 2020;11:3031. doi: 10.1038/s41467-020-16820-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16820-6</ArticleId><ArticleId IdType="pmc">PMC7295996</ArticleId><ArticleId IdType="pubmed">32541785</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse A, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296&#x2013;W303. doi: 10.1093/nar/gky427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky427</ArticleId><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaszczyk J, et al. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry. 2000;39:14075&#x2013;14081. doi: 10.1021/bi0009340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0009340</ArticleId><ArticleId IdType="pubmed">11087354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>